Hong Kong's ORI hits first close on Fund II, exits Kymab
Hong Kong healthcare-focused VC firm ORI Capital has reached a first close of $112 million on its second fund and exited its largest investment, UK biotech developer Kymab, as part of a $1.1 billion deal.
A second close that would take Fund II past 50% of its $400 million target is currently being finalized, according to a source familiar with the situation. A third close is expected by the end of 2021....
More on Greater China
Latest News
China 3D printing start-up WeNext raises $55m
Temasek Holdings, Cathay Capital Private Equity, and Haochen Capital have led a $55 million Series B round for WeNext Technology, a China-based 3D printing specialist.
Vision Fund backs Japan sneaker marketplace
SoftBank Vision Fund 2 has made a Series D investment of undisclosed size in Japan’s Soda, operator of sneaker reselling platform Snkr Dunk, at a valuation of JPY38 billion ($336 million).
Chinese language learning platform raises $105m
Singapore’s LingoAce, a Chinese language learning app, has raised $105 million in Series C funding led by Sequoia Capital India. It comes within a year of a $55 million Series B.
CVC backs take-private of Hong Kong-listed Razer
CVC Capital Partners is supporting a proposed founder-led privatization of Hong Kong-listed gaming hardware and software provider Razer that values the business at HK$24.7 billion ($3.17 billion).